On October 6, Charles River Laboratories rose 5.24% in regular trading, reaching $327.04 per share with turnover of $43.21 million.

The move follows UBS's September 30 upgrade of the stock from Neutral to Buy, with its price target raised from $175 to $357 — substantially above the analyst consensus mean target of $423.54. The sharp revision signals renewed institutional confidence in the company's long-term growth trajectory.

Additionally, Charles River has expanded its business across GLP-1 related testing, vaccine R&D collaboration, and digital laboratory execution. Its partnership with Autolomous leverages the autoloMATE lab execution system to digitize and automate GMP quality-control workflows across North American and European biologics testing sites. Earlier agreements with PMGC's NorthStrive Biosciences unit added plasmid copy-number testing for probiotic candidates supporting GLP-1 weight-loss therapies, further diversifying its revenue pipeline.

Multiple sell-side institutions, including JPMorgan, Evercore ISI, and RBC, have also raised their price targets in recent months, reinforcing the positive sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)